Treating gastrointestinal malignancy with proton therapy
The improved dosimetry with proton therapy enables greater sparing of normal tissues...
The improved dosimetry with proton therapy enables greater sparing of normal tissues...
Worldwide, lung cancer is the most common cancer among men in both incidence and...
During ISOP 2022, James Mets presented The State of Proton Therapy in the U.S. Watch the webinar above.
This study evaluated 68 patients with atypical teratoid/rhabdoid tumors (ATRT) treated with surgery (65% initial gross total resection or GTR), chemotherapy (60...
This study analyzed 124 patients who underwent proton therapy with gastrointestinal tract involved in the irradiated field. The study reported gastrointestinal...
This study presented outcomes of a prospective multicenter trial with an early closure. Twenty-eight patients with stage II or III unresectable NSCLC were...
With data of 41 patients with stage III NSCLC who received PBT of 74 GyE with concurrent chemotherapy, this study reported that bone V5-20 and lung V5-50 were...
This study retrospectively review 69 patients with esophageal cancer treated with XRT (n=15) and PBT (n= 54) and concurrent chemotherapy. The study found that...
This study compared the results of 31 patients with locally advanced esophageal cancer treated with neoadjuvant chemoradiotherapy to a median total dose 41.4 Gy...